A randomized trial of low-dose, topical mitomycin-C in the treatment of severe vernal keratoconjunctivitis

Akpek, Esen K.; Hasıripi, Hikmet; Christen, William G.; Kalayci, Defne

doi:10.1016/s0161-6420(99)00096-2

Cited by 49 publications

(44 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A signifi cant decrease in signs and symptoms compared with the placebo group was shown at the end of the 2-week treatment period [ 4 ]. Nevertheless, mitomycin-C is not approved for treatment of VKC.…”

Section: Cyclosporine and Other Immunosuppressive Treatments In Vkcmentioning

confidence: 95%

Ocular Allergy

Leonardi¹,

Barney²

2014

Immune Modulation and Anti-Inflammatory Therapy in Ocular Disorders

View full text Add to dashboard Cite

Section: Cyclosporine and Other Immunosuppressive Treatments In Vkcmentioning

confidence: 95%

Ocular Allergy

Leonardi¹,

Barney²

2014

Immune Modulation and Anti-Inflammatory Therapy in Ocular Disorders

View full text Add to dashboard Cite

“…Mitomycin-C (0,01%)-Augentropfen konnten Mukusbildung und morphologische Befunde nach Versagen von lokalen Steroiden und Mastzellstabilisatoren positiv beeinflussen [29]. Liegen extraokulare allergische Beteiligungen vor (Rhinitis, Asthma, Ekzem) oder spricht die lokale Therapie im akuten Stadium nicht an, können systemische Kortikosteroide kurzzeitig effektiv eingesetzt werden.…”

Section: Antimetaboliteunclassified

Keratoconjunctivitis vernalis

Pleyer

Leonardi

2015

Ophthalmologe

View full text Add to dashboard Cite

Vernal keratoconjunctivitis (VKC) is a bilateral, usually seasonally recurrent inflammation of the conjunctiva. Clinically characteristic findings are tarsal giant conjunctival papillae (> 1 mm) and/or limbal gelatinous changes (Trantas dots). The underlying etiology and pathophysiology of VKC remains unclear; however, clinical findings and immunohistochemical studies suggest a complex, both IgE-dependent and IgE-independent immune-mediated etiology. Several predisposing conditions include endocrine, genetic, neurogenic, environmental and socioeconomic risk factors. Mast cell stabilizers, antihistamines and topical corticosteroids are often used during acute flare-ups in VKC; however this approach is unsatisfactory for controlling severe cases and avoiding recurrences. Immunomodulatory agents, such as cyclosporin A and tacrolimus are promising alternative agents for long-term management. In most children the clinical course of VKC is self-limiting and may disappear following puberty; however, some VKC patients will face sight-threatening complications which are mainly due to corneal involvement and iatrogenic damage caused by prolonged corticosteroid treatment.

show abstract

“…1 Signs and symptoms of VKC show exacerbations during spring and summer seasons, but a small percentage of patients have the perennial form. 2 Diagnosis of this allergic condition is done by the presence of characteristic clinical features which consist of itching, tearing, mucous discharge, conjunctival hyperemia, cobblestone papillae seen over upper tarsal conjunctiva, Tranta's spots over the limbus, and superficial keratitis. Severe corneal involvements in the form of shield ulceration and conjunctival cicatrization are sight threatening.…”

Section: Introductionmentioning

confidence: 99%